Skip to main content

Advertisement

SpringerLink
Log in

Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although patients with prostate cancer with metastatic lesions initially respond to androgen ablation therapy, most patients ultimately develop a hormone-refractory state. Effective treatment for men with hormone-refractory prostate cancer (HRPC) has not been established. We performed a clinical study of docetaxel in HRPC patients, and evaluated its efficacy.

Methods

Nine patients with HRPC were administered 55 mg/m2 docetaxel, every 3 weeks, simultaneously with hormonal therapy, with a luteinizing hormone-releasing hormone analog, and daily oral dexamethasone. Change in serum prostate-specific antigen (PSA) was determined as the primary endpoint.

Results

The mean age of the patients was 64 years (range, 49 to 76 years). Median follow-up time was 8.5 months (range, 5.3 to 16.7 months). In eight patients whose pretreatment serum PSA was elevated, six patients (75.0%) had a PSA decline of more than 50%, and four (50.0%) had a PSA decline of more than 75%. Median time to progression for all patients was 7.9 months (range, 0.0 to 11.6 months; 95% confidence interval [CI], 0.0 to 26.3). The median overall survival was 8.5 months (range, 5.3 to 16.7 months; 95% CI, 8.1 to 13.8). Four of six patients (66.7%) with pain before treatment obtained pain relief and were able to discontinue analgesic agents. This regimen was well tolerated. Grade 3 or 4 neutropenia or leukocytopenia without fever was seen in three patients (33.3%). Only one patient required administration of granulocyte-colony stimulating factor because of neutropenia. No other grade 3 or 4 toxicity was observed.

Conclusion

Docetaxel was an active agent in Japanese HRPC patients, and was well tolerated in this population. To establish its efficacy and safety in Japanese HRPC patients, a large-scale study in Japan is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. SL Parker T Tong S Bolden et al. (1997) ArticleTitleCancer statistics, 1997 CA Cancer J Clin 47 5–27 Occurrence Handle1:STN:280:ByiC2cbis1w%3D Occurrence Handle8996076

    CAS  PubMed  Google Scholar 

  2. Vital Statistics of Japan, Statistics and Information Department. Tokyo: Minister’s Secretariat, Ministry of Health, Labor and Welfare

  3. C Huggins C Hodges (1941) ArticleTitleStudies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293–297 Occurrence Handle1:CAS:528:DyaH3MXkvVCrtw%3D%3D

    CAS  Google Scholar 

  4. EJ Small NJ Vogelzang (1997) ArticleTitleSecond-line hormonal therapy for advanced prostate cancer: a shifting paradigm J Clin Oncol 15 382–388 Occurrence Handle1:CAS:528:DyaK2sXnsV2ltg%3D%3D Occurrence Handle8996165

    CAS  PubMed  Google Scholar 

  5. WK Oh PW Kantoff (1998) ArticleTitleManagement of hormone refractory prostate cancer: current standards and future prospects J Urol 160 1220–1229 Occurrence Handle10.1097/00005392-199810000-00003 Occurrence Handle1:CAS:528:DyaK1MXitFym Occurrence Handle9751323

    Article  CAS  PubMed  Google Scholar 

  6. ML Slevin L Stubbs HJ Plant et al. (1990) ArticleTitleAttitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public BMJ 300 1458–1460 Occurrence Handle1:STN:280:By%2BA3srltVA%3D Occurrence Handle2379006

    CAS  PubMed  Google Scholar 

  7. IF Tannock D Osoba MR Stockler et al. (1996) ArticleTitleChemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756–1764 Occurrence Handle1:CAS:528:DyaK28XjslOrsr8%3D Occurrence Handle8656243

    CAS  PubMed  Google Scholar 

  8. PW Kantoff S Halabi M Conaway et al. (1999) ArticleTitleHydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 2506–2513 Occurrence Handle1:CAS:528:DyaK1MXltlyltL8%3D

    CAS  Google Scholar 

  9. JF Diaz JM Andreu (1993) ArticleTitleAssembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition Biochemistry 32 2747–2755 Occurrence Handle10.1021/bi00062a003 Occurrence Handle1:CAS:528:DyaK3sXhs1Slt7k%3D Occurrence Handle8096151

    Article  CAS  PubMed  Google Scholar 

  10. S Haldar A Basu CM Croce (1997) ArticleTitleBcl2 is the guardian of microtubule integrity Cancer Res 57 229–233 Occurrence Handle1:CAS:528:DyaK2sXntFKisQ%3D%3D Occurrence Handle9000560

    CAS  PubMed  Google Scholar 

  11. W Kreis DR Budman A Calabro (1997) ArticleTitleUnique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines Br J Urol 79 196–202 Occurrence Handle1:CAS:528:DyaK2sXhsFeqtrc%3D Occurrence Handle9052470

    CAS  PubMed  Google Scholar 

  12. JF Williams HJ Muenchen JM Kamradt et al. (2000) ArticleTitleTreatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study Prostate 44 275–278 Occurrence Handle10.1002/1097-0045(20000901)44:4<275::AID-PROS3>3.0.CO;2-9 Occurrence Handle1:CAS:528:DC%2BD3cXmsF2gsbs%3D Occurrence Handle10951491

    Article  CAS  PubMed  Google Scholar 

  13. J Picus M Schultz (1999) ArticleTitleDocetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results Semin Oncol 26 14–18 Occurrence Handle1:CAS:528:DC%2BD3cXivVahtw%3D%3D

    CAS  Google Scholar 

  14. W Berry S Dakhil MA Gregurich et al. (2001) ArticleTitlePhase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 8–15 Occurrence Handle10.1053/sonc.2001.26893 Occurrence Handle1:CAS:528:DC%2BD3MXotVemsbs%3D

    Article  CAS  Google Scholar 

  15. TM Beer WC Pierce BA Lowe (2001) ArticleTitlePhase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 1273–1279 Occurrence Handle10.1023/A:1012258723075 Occurrence Handle1:STN:280:DC%2BD3MnksFGntA%3D%3D Occurrence Handle11697840

    Article  CAS  PubMed  Google Scholar 

  16. IF Tannock R de Wit WR Berry et al. (2004) ArticleTitleDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502–1512 Occurrence Handle10.1056/NEJMoa040720 Occurrence Handle1:CAS:528:DC%2BD2cXot1Kmu7s%3D Occurrence Handle15470213

    Article  CAS  PubMed  Google Scholar 

  17. DP Petrylak R Macarthur J O’Connor et al. (1999) ArticleTitlePhase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer Semin Oncol 26 28–33 Occurrence Handle1:CAS:528:DC%2BD3cXivVahtQ%3D%3D

    CAS  Google Scholar 

  18. DP Petrylak RB Macarthur J O’Connor et al. (1999) ArticleTitlePhase I trial of docetaxel with estramustine in androgen-independent prostate cancer J Clin Oncol 17 958–967 Occurrence Handle1:CAS:528:DyaK1MXhvFGgu7k%3D Occurrence Handle10071290

    CAS  PubMed  Google Scholar 

  19. W Kreis DR Budman J Fetten et al. (1999) ArticleTitlePhase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma Ann Oncol 10 33–38 Occurrence Handle10.1023/A:1008354600497 Occurrence Handle1:STN:280:DyaK1M7ns1Sitw%3D%3D

    Article  CAS  Google Scholar 

  20. DP Petrylak CM Tangen MH Hussain et al. (2004) ArticleTitleDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513–1520 Occurrence Handle10.1056/NEJMoa041318 Occurrence Handle1:CAS:528:DC%2BD2cXot1Kmu7c%3D Occurrence Handle15470214

    Article  CAS  PubMed  Google Scholar 

  21. InstitutionalAuthorNameJapanese Urological Association and The Japanese Society of Pathology (2001) General rule for clinical and pathological studies on prostate cancer EditionNumber3 Kanehara Tokyo

    Google Scholar 

  22. I Tannock M Gospodarowicz W Meakin et al. (1989) ArticleTitleTreatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 590–597 Occurrence Handle1:STN:280:BiaB3MrpsFc%3D Occurrence Handle2709088

    CAS  PubMed  Google Scholar 

  23. RE Millikan (1999) ArticleTitleChemotherapy of advanced prostatic carcinoma Semin Oncol 26 185–191 Occurrence Handle1:CAS:528:DyaK1MXivFSrtr0%3D Occurrence Handle10597729

    CAS  PubMed  Google Scholar 

  24. M Hussain DC Smith BF El-Rayes et al. (2003) ArticleTitleNeoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer Urology 61 774–780 Occurrence Handle10.1016/S0090-4295(02)02519-0 Occurrence Handle12670564

    Article  PubMed  Google Scholar 

  25. T Kojima T Shimazui M Onozawa et al. (2004) ArticleTitleWeekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients Jpn J Clin Oncol 34 137–141 Occurrence Handle10.1093/jjco/hyh021 Occurrence Handle15078909

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Yasuhide Miyoshi, Hiroji Uemura, Masafumi Nakamura, Hisashi Hasumi, Shinpei Sugiura, Kazuhide Makiyama, Noboru Nakaigawa, Takeshi Kishida, Takehiko Ogawa, Masahiro Yao & Yoshinobu Kubota

Authors
  1. Yasuhide Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroji Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masafumi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisashi Hasumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinpei Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhide Makiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noboru Nakaigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Kishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takehiko Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiro Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshinobu Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhide Miyoshi.

About this article

Cite this article

Miyoshi, Y., Uemura, H., Nakamura, M. et al. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 10, 182–186 (2005). https://doi.org/10.1007/s10147-005-0490-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-005-0490-0

Key words

Search

Navigation